指南与共识炎症性肠病

美国胃肠病学会临床实践指南:生物标志物在克罗恩病管理中的作用

AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease.
指南 / 共识 · Gastroenterology · 2023-01-01

美国胃肠病学会采用GRADE框架制定指南,评估粪便钙卫蛋白、血清C反应蛋白和Endoscopic Healing Index在已确诊克罗恩病患者中的表现,以简单内镜评分≥3为内镜活动金标准,共形成11条条件性推荐,覆盖症状缓解、轻至重度症状及术后缓解等场景。

要点

  • 症状缓解期建议采用生物标志物联合症状的监测策略,优于仅监测症状。
  • 症状缓解期粪便钙卫蛋白<150 μg/g且C反应蛋白正常可排除活动性炎症,避免内镜检查评估疾病活动度。
  • 中度至重度症状患者粪便钙卫蛋白或血清C反应蛋白升高提示内镜活动,可不行常规内镜评估疾病活动度。

核心结论

  • 在克罗恩病患者中,粪便钙卫蛋白和血清C反应蛋白可为无症状和有症状患者的疾病管理提供信息。
  • 症状评估与生物标志物值不一致时,可能需内镜评估以确认疾病活动状态。

研究设计与样本

  • 美国胃肠病学会(AGA)指南,由内容专家和指南方法学家组成的多学科小组采用推荐分级的评估、制定与评价(GRADE)框架制定。
  • 证据评估对象为已确诊克罗恩病、无症状、有不同严重程度症状或手术诱导缓解的患者,评估粪便钙卫蛋白、血清C反应蛋白和Endoscopic Healing Index的表现。
  • 生物标志物表现以简单克罗恩病内镜评分(SES-CD)≥3定义的内镜活动为金标准进行评价。

主要发现

  • 指南小组共形成11条条件性推荐。
  • 症状缓解期粪便钙卫蛋白<150 μg/g且C反应蛋白正常可排除活动性炎症,避免内镜检查评估疾病活动度。
  • 症状缓解期生物标志物升高者,调整治疗前需内镜确认。
  • 轻度症状患者中,生物标志物正常或升高均不足以准确判断内镜活动。
  • 中度至重度症状患者中,粪便钙卫蛋白或血清C反应蛋白升高提示内镜活动,可不行常规内镜评估疾病活动度。

关键数值与推荐

  • 症状缓解期:建议采用生物标志物联合症状的监测策略优于仅监测症状(条件性推荐)。
  • 症状缓解期:粪便钙卫蛋白<150 μg/g且C反应蛋白正常可排除活动性炎症,避免内镜评估疾病活动度(条件性推荐)。
  • 症状缓解期:生物标志物升高者调整治疗前需内镜确认(条件性推荐)。
  • 轻度症状:生物标志物正常或升高均不足以准确判断内镜活动(条件性推荐)。
  • 中度至重度症状:粪便钙卫蛋白或血清C反应蛋白升高提示内镜活动,可不行常规内镜评估疾病活动度(条件性推荐)。

临床怎么用

  • 症状缓解期可采用生物标志物联合症状的监测策略。
  • 症状缓解期粪便钙卫蛋白<150 μg/g且C反应蛋白正常时,可避免内镜评估疾病活动度。
  • 症状缓解期生物标志物升高时,调整治疗前需内镜确认。
  • 中度至重度症状患者粪便钙卫蛋白或血清C反应蛋白升高时,可不行常规内镜评估疾病活动度。
  • 手术诱导缓解的低风险药物预防患者粪便钙卫蛋白正常可排除内镜复发;其他术后情况建议内镜评估以确定术后复发。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Biomarkers are used frequently for evaluation and monitoring of patients with Crohn's disease (CD). This American Gastroenterological Association (AGA) guideline is intended to support practitioners in decisions about the use of biomarkers for the management of CD. METHODS: A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to formulate patient-centered clinical questions and review evidence on the performance of fecal calprotectin, serum C-reactive protein (CRP), and Endoscopic Healing Index in patients with established CD who were asymptomatic, had symptoms of varying severity, or were in surgically induced remission. Biomarker performance was assessed against the gold standard of endoscopic activity, defined as a Simple Endoscopic Score for Crohn's Disease ≥3. The panel used the Grading of Recommendations Assessment, Development and Evaluation Evidence-to-Decision framework to develop recommendations for use of biomarkers in various settings. Implementation considerations were formulated for each recommendation to inform clinical practice. RESULTS: The guideline panel made 11 conditional recommendations. In patients with CD in symptomatic remission, the panel suggests use of a biomarker- and symptom-based monitoring strategy over symptoms alone. In patients in symptomatic remission, a fecal calprotectin <150 μg/g and normal CRP rules out active inflammation, avoiding endoscopic evaluation for assessment of disease activity. However, elevated biomarkers in this setting merit confirmation with endoscopy before treatment adjustment. In patients with CD with mild symptoms, neither normal nor elevated biomarkers alone are sufficiently accurate to determine endoscopic activity. In patients with CD with moderate to severe symptoms, elevated fecal calprotectin or serum CRP suggests endoscopic activity, precluding routine endoscopic assessment for disease activity. In patients with CD in surgically induced remission in low-risk patients on pharmacologic prophylaxis, a normal fecal calprotectin reliably rules out endoscopic recurrence. In other postoperative settings, the panel suggests endoscopic assessment for establishing postoperative recurrence. CONCLUSIONS: In patients with CD, fecal calprotectin and serum CRP can inform disease management in both asymptomatic and symptomatic disease. Discordance between symptom assessment and biomarker value may merit endoscopic evaluation for confirmation of status of disease activity.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Ananthakrishnan AN, Adler J, Chachu KA, et al. AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease. Gastroenterology. 2023. PMID: 37981354. doi:10.1053/j.gastro.2023.09.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。